Cargando…

An overview of SARS-COV-2 epidemiology, mutant variants, vaccines, and management strategies

BACKGROUND: Over the last two decades, humanity has observed the extraordinary anomaly caused by novel, weird coronavirus strains, such as severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). As the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) virus h...

Descripción completa

Detalles Bibliográficos
Autores principales: Farooqi, Tahmeena, Malik, Jonaid Ahmad, Mulla, Almas Hanif, Al Hagbani, Turki, Almansour, Khaled, Ubaid, Mohammed Abrar, Alghamdi, Saleh, Anwar, Sirajudheen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8366110/
https://www.ncbi.nlm.nih.gov/pubmed/34429257
http://dx.doi.org/10.1016/j.jiph.2021.08.014
_version_ 1783738844074475520
author Farooqi, Tahmeena
Malik, Jonaid Ahmad
Mulla, Almas Hanif
Al Hagbani, Turki
Almansour, Khaled
Ubaid, Mohammed Abrar
Alghamdi, Saleh
Anwar, Sirajudheen
author_facet Farooqi, Tahmeena
Malik, Jonaid Ahmad
Mulla, Almas Hanif
Al Hagbani, Turki
Almansour, Khaled
Ubaid, Mohammed Abrar
Alghamdi, Saleh
Anwar, Sirajudheen
author_sort Farooqi, Tahmeena
collection PubMed
description BACKGROUND: Over the last two decades, humanity has observed the extraordinary anomaly caused by novel, weird coronavirus strains, such as severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). As the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) virus has made its entry into the world, it has dramatically affected life in every domain by continuously producing new variants. The vaccine development is an ongoing process, although some vaccines got marketed. The big challenge is now whether the vaccine candidates can provide long-lasting protection or prevention against mutant variants. METHODS: The information was gathered from various journals, electronic searches via Internet-based information such as PubMed, Google Scholar, Science Direct, online electronic journals, WHO landscape, world meters, WHO website, and News. RESULTS: This review will present and discuss some coronavirus disease 19 (COVID-19) related aspects including: the pathophysiology, epidemiology, mutant variants vaccine candidates, vaccine efficacy, and management strategies. Due to the high death rate, continuous spread, an inadequate workforce, lack of required therapeutics, and incomplete understanding of the viral strain, it becomes crucial to build the knowledge of its biological characteristics and make available the rapid diagnostic and vital therapeutic machinery for the combat and management of an infection. CONCLUSION: The data summarizes current research on the COVID 19 infection and therapeutic interventions, which will direct future decision-making on the effort-worthy phases of the COVID 19 and the development of critical therapeutics. The only possible solution is the vaccine development targeting against all variant strains to halt its progress; the identified theoretical and practical knowledge can eliminate the gaps to improve a better understanding of the novel coronavirus structure and its design of a vaccine. In addition, to that the long-lasting protection is another challenging objective that need to be looked into.
format Online
Article
Text
id pubmed-8366110
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The Authors. Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences.
record_format MEDLINE/PubMed
spelling pubmed-83661102021-08-16 An overview of SARS-COV-2 epidemiology, mutant variants, vaccines, and management strategies Farooqi, Tahmeena Malik, Jonaid Ahmad Mulla, Almas Hanif Al Hagbani, Turki Almansour, Khaled Ubaid, Mohammed Abrar Alghamdi, Saleh Anwar, Sirajudheen J Infect Public Health Review Article BACKGROUND: Over the last two decades, humanity has observed the extraordinary anomaly caused by novel, weird coronavirus strains, such as severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). As the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) virus has made its entry into the world, it has dramatically affected life in every domain by continuously producing new variants. The vaccine development is an ongoing process, although some vaccines got marketed. The big challenge is now whether the vaccine candidates can provide long-lasting protection or prevention against mutant variants. METHODS: The information was gathered from various journals, electronic searches via Internet-based information such as PubMed, Google Scholar, Science Direct, online electronic journals, WHO landscape, world meters, WHO website, and News. RESULTS: This review will present and discuss some coronavirus disease 19 (COVID-19) related aspects including: the pathophysiology, epidemiology, mutant variants vaccine candidates, vaccine efficacy, and management strategies. Due to the high death rate, continuous spread, an inadequate workforce, lack of required therapeutics, and incomplete understanding of the viral strain, it becomes crucial to build the knowledge of its biological characteristics and make available the rapid diagnostic and vital therapeutic machinery for the combat and management of an infection. CONCLUSION: The data summarizes current research on the COVID 19 infection and therapeutic interventions, which will direct future decision-making on the effort-worthy phases of the COVID 19 and the development of critical therapeutics. The only possible solution is the vaccine development targeting against all variant strains to halt its progress; the identified theoretical and practical knowledge can eliminate the gaps to improve a better understanding of the novel coronavirus structure and its design of a vaccine. In addition, to that the long-lasting protection is another challenging objective that need to be looked into. The Authors. Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences. 2021-10 2021-08-16 /pmc/articles/PMC8366110/ /pubmed/34429257 http://dx.doi.org/10.1016/j.jiph.2021.08.014 Text en © 2021 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Review Article
Farooqi, Tahmeena
Malik, Jonaid Ahmad
Mulla, Almas Hanif
Al Hagbani, Turki
Almansour, Khaled
Ubaid, Mohammed Abrar
Alghamdi, Saleh
Anwar, Sirajudheen
An overview of SARS-COV-2 epidemiology, mutant variants, vaccines, and management strategies
title An overview of SARS-COV-2 epidemiology, mutant variants, vaccines, and management strategies
title_full An overview of SARS-COV-2 epidemiology, mutant variants, vaccines, and management strategies
title_fullStr An overview of SARS-COV-2 epidemiology, mutant variants, vaccines, and management strategies
title_full_unstemmed An overview of SARS-COV-2 epidemiology, mutant variants, vaccines, and management strategies
title_short An overview of SARS-COV-2 epidemiology, mutant variants, vaccines, and management strategies
title_sort overview of sars-cov-2 epidemiology, mutant variants, vaccines, and management strategies
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8366110/
https://www.ncbi.nlm.nih.gov/pubmed/34429257
http://dx.doi.org/10.1016/j.jiph.2021.08.014
work_keys_str_mv AT farooqitahmeena anoverviewofsarscov2epidemiologymutantvariantsvaccinesandmanagementstrategies
AT malikjonaidahmad anoverviewofsarscov2epidemiologymutantvariantsvaccinesandmanagementstrategies
AT mullaalmashanif anoverviewofsarscov2epidemiologymutantvariantsvaccinesandmanagementstrategies
AT alhagbaniturki anoverviewofsarscov2epidemiologymutantvariantsvaccinesandmanagementstrategies
AT almansourkhaled anoverviewofsarscov2epidemiologymutantvariantsvaccinesandmanagementstrategies
AT ubaidmohammedabrar anoverviewofsarscov2epidemiologymutantvariantsvaccinesandmanagementstrategies
AT alghamdisaleh anoverviewofsarscov2epidemiologymutantvariantsvaccinesandmanagementstrategies
AT anwarsirajudheen anoverviewofsarscov2epidemiologymutantvariantsvaccinesandmanagementstrategies
AT farooqitahmeena overviewofsarscov2epidemiologymutantvariantsvaccinesandmanagementstrategies
AT malikjonaidahmad overviewofsarscov2epidemiologymutantvariantsvaccinesandmanagementstrategies
AT mullaalmashanif overviewofsarscov2epidemiologymutantvariantsvaccinesandmanagementstrategies
AT alhagbaniturki overviewofsarscov2epidemiologymutantvariantsvaccinesandmanagementstrategies
AT almansourkhaled overviewofsarscov2epidemiologymutantvariantsvaccinesandmanagementstrategies
AT ubaidmohammedabrar overviewofsarscov2epidemiologymutantvariantsvaccinesandmanagementstrategies
AT alghamdisaleh overviewofsarscov2epidemiologymutantvariantsvaccinesandmanagementstrategies
AT anwarsirajudheen overviewofsarscov2epidemiologymutantvariantsvaccinesandmanagementstrategies